Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare...

Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus
on Healthcare Conference

SAN DIEGO, July 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5,
2009 at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) at the Millennium
Broadway Hotel in New York City. Jack Lief, Arena's President and Chief
Executive Officer, is scheduled to provide an overview of the company,
including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor
relations section of Arena's website at www.arenapharm.com. A replay of the
presentation will be available for 30 days following the event. Please connect
to Arena's website several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing oral drugs in four major therapeutic areas:
cardiovascular, central nervous system, inflammatory and metabolic diseases.
Arena's most advanced drug candidate, lorcaserin, is being investigated in a
Phase 3 clinical trial program for weight management. Arena's broad pipeline
of novel compounds target G protein-coupled receptors, an important class of
validated drug targets, and includes compounds being evaluated independently
and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen
Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that
involve a number of risks and uncertainties. Such forward-looking statements
include statements about Arena's strategy, internal and partnered programs,
and ability to develop compounds and commercialize drugs. For such statements,
Arena claims the protection of the Private Securities Litigation Reform Act of
1995. Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ materially
from the forward-looking statements include, but are not limited to, the
timing, success and cost of Arena's lorcaserin program and other of its
research and development programs; results of clinical trials or preclinical
studies may not be predictive of future results; clinical trials and studies
may not proceed at the time or in the manner Arena expects or at all; Arena's
ability to partner lorcaserin or other of its compounds or programs; the
timing and ability of Arena to receive regulatory approval for its drug
candidates; Arena's ability to obtain additional funds; Arena's ability to
obtain and defend its patents; and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
Contacts: Jack Lief
President and Chief Executive Officer

Cindy McGee
Senior Communications Associate

Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1479

SOURCE Arena Pharmaceuticals, Inc.

Jack Lief, President and Chief Executive Officer, or Cindy McGee, Senior
Communications Associate, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200, Ext. 1479